Vitamin D - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.67 [0.07, 6.87]< 155%2 studies (2/-)63.0 %some concernnot evaluable moderatecrucial-
hospital discharge 0.99 [0.71, 1.38]> 10%1 study (1/-)47.6 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.49 [0.21, 1.14]< 10%1 study (1/-)95.1 %some concernnot evaluable moderateimportant-
ICU admission 0.17 [0.01, 3.79]< 186%2 studies (2/-)86.4 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 0.99 [0.02, 50.39]< 10%1 study (1/-)50.2 %some concernnot evaluable moderateimportant-
adverse events 1.99 [0.07, 59.94]< 10%1 study (1/-)34.8 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.